Cargando…
Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?
BACKGROUND: The recent outbreak of COVID-19 has raised concerns in the rheumatology community about the management of immunosuppressed patients diagnosed with inflammatory rheumatic diseases. It is not clear whether the use of biological agents may suppose a risk or protection against SARS-CoV-2 inf...
Autores principales: | Santos, Cristiana Sieiro, Férnandez, Xenia Cásas, Moriano Morales, Clara, Álvarez, Elvira Díez, Álvarez Castro, Carolina, López Robles, Alejandra, Pérez Sandoval, Trinidad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813407/ https://www.ncbi.nlm.nih.gov/pubmed/33455920 http://dx.doi.org/10.1136/rmdopen-2020-001439 |
Ejemplares similares
-
Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases
por: Sieiro Santos, Cristiana, et al.
Publicado: (2022) -
Clinical phenotype in scleroderma patients based on autoantibodies
por: Santos, Cristiana Sieiro, et al.
Publicado: (2023) -
Determinants of COVID-19 disease severity in patients with underlying rheumatic disease
por: Santos, C. Sieiro, et al.
Publicado: (2020) -
Akkermansia muciniphila in neuropsychiatric disorders: friend or foe?
por: Lei, Wenhui, et al.
Publicado: (2023) -
Saliva—Friend and Foe in the COVID-19 Outbreak
por: Han, Pingping, et al.
Publicado: (2020)